See more : Ediston Property Investment Company plc (EPIC.L) Income Statement Analysis – Financial Results
Complete financial analysis of DIAGNOS Inc. (DGNOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DIAGNOS Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- PT GTS Internasional Tbk (GTSI.JK) Income Statement Analysis – Financial Results
- Hyosung TNC Corporation (298020.KS) Income Statement Analysis – Financial Results
- M Vision Public Company Limited (MVP.BK) Income Statement Analysis – Financial Results
- XTL Biopharmaceuticals Ltd. (XTLB.TA) Income Statement Analysis – Financial Results
- Fast Retailing Co., Ltd. (9983.T) Income Statement Analysis – Financial Results
DIAGNOS Inc. (DGNOF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.diagnos.ca
About DIAGNOS Inc.
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.16K | 438.83K | 267.07K | 331.52K | 326.47K | 326.47K | 1.61M | 2.39M | 981.48K | 564.18K | 2.70M | 1.51M | 1.33M | 1.07M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Cost of Revenue | 1.01M | 857.13K | 614.60K | 804.97K | 1.09M | 1.09M | 1.32M | 1.67M | 1.18M | 1.11M | 2.24M | 1.02M | 104.54K | 24.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -837.94K | -418.30K | -347.53K | -473.46K | -759.37K | -759.37K | 290.90K | 719.10K | -203.51K | -541.43K | 464.53K | 490.00K | 1.22M | 1.05M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Gross Profit Ratio | -492.45% | -95.32% | -130.13% | -142.81% | -232.60% | -232.60% | 18.04% | 30.09% | -20.73% | -95.97% | 17.17% | 32.47% | 92.13% | 97.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 1.08M | 603.35K | 0.00 | 0.00 | 0.00 | 922.49K | 0.00 | 1.18M | 1.07M | 1.31M | 1.00M | 831.56K | 793.96K | 614.13K | 618.21K | 674.24K | 193.82K | 101.25K | 179.58K | 784.10K | -4.56K | 192.92K | 1.44M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.84M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -293.72K | -295.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.77M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 2.46M | 2.10M | 1.69M | 3.23M | 2.02M | 1.39M | 1.09M | 1.10M | 426.23K | 567.04K | 1.45M |
| Other Expenses | 0.00 | 100.14K | 264.28K | 85.80K | 52.31K | 52.31K | 0.00 | 0.00 | 1.07M | 0.00 | 0.00 | -374.80K | -240.63K | -204.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.76M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 3.15M | 2.66M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Cost & Expenses | 3.86M | 3.10M | 2.55M | 3.13M | 3.26M | 3.26M | 4.08M | 4.36M | 3.70M | 3.23M | 4.35M | 3.56M | 3.25M | 2.69M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Interest Income | 6.89K | 5.38K | 5.38K | 3.23K | 3.23K | 1.48K | 0.00 | 0.00 | 0.00 | 0.00 | 5.23K | 11.89K | 27.01K | 8.79K | 15.44K | 76.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 550.17K | 53.78K | 32.16K | 347.11K | 1.03M | 1.03M | 827.77K | 955.38K | 469.22K | 159.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.25K | 0.00 | 0.00 |
| Depreciation & Amortization | 124.21K | 101.17K | 105.80K | 92.84K | 101.72K | 191.32K | 230.19K | 192.65K | 82.37K | 43.71K | 62.19K | 89.52K | 81.36K | 125.94K | 186.17K | 188.36K | 79.67K | 32.68K | 29.28K | 23.66K | 75.05K | 139.36K | 176.19K |
| EBITDA | -2.45M | -2.10M | -2.45M | -2.61M | -2.69M | -2.69M | -2.66M | -1.78M | -2.64M | -2.62M | -1.58M | -1.97M | -1.84M | -1.49M | -1.74M | -1.97M | -347.40K | -711.98K | -560.21K | -1.77M | -33.96K | -631.34K | -2.88M |
| EBITDA Ratio | -1,437.61% | -557.99% | -723.29% | -785.96% | -822.85% | -822.39% | -164.64% | -74.54% | -269.07% | -465.19% | -58.55% | -130.30% | -134.65% | -184.81% | -485.96% | -104.35% | -18.65% | -91.78% | -78.99% | -1,587.96% | -8.76% | -490.86% | -41,123.96% |
| Operating Income | -3.69M | -2.55M | -2.02M | -2.71M | -2.88M | -2.88M | -2.89M | -1.97M | -2.72M | -2.67M | -1.65M | -2.06M | -2.22M | -1.58M | -1.93M | -2.16M | -427.07K | -744.66K | -589.49K | -1.80M | -109.01K | -770.70K | -3.05M |
| Operating Income Ratio | -2,168.30% | -582.10% | -756.03% | -816.65% | -881.45% | -881.00% | -178.91% | -82.60% | -277.46% | -472.94% | -60.85% | -136.23% | -167.19% | -147.33% | -537.96% | -114.34% | -22.92% | -96.00% | -83.12% | -1,609.13% | -28.12% | -599.21% | -43,640.96% |
| Total Other Income/Expenses | 568.95K | -259.14K | 608.66K | 232.12K | -505.21K | -1.03M | -622.77K | 232.83K | 475.50K | -159.40K | 5.23K | 11.89K | 27.01K | 275.63K | 0.00 | 0.00 | 0.00 | 124.41K | 8.37K | 64.85K | 26.20K | -57.70K | -123.17K |
| Income Before Tax | -3.12M | -2.61M | -2.05M | -3.38M | -3.90M | -3.90M | -3.09M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | 0.00 | 0.00 | 0.00 | -620.25K | -581.12K | -1.73M | -82.81K | -828.40K | -3.18M |
| Income Before Tax Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,195.74% | -1,195.74% | -191.55% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | 0.00% | 0.00% | 0.00% | -79.96% | -81.94% | -1,551.10% | -21.36% | -644.07% | -45,400.57% |
| Income Tax Expense | 0.00 | 153.92K | 296.44K | 432.91K | -64.67K | -64.67K | -192.19K | -1.32M | 0.00 | 0.00 | 0.00 | -540.22K | 28.02K | -508.81K | -15.44K | -76.43K | -28.99K | -3.12K | 747.00 | 12.79K | 47.25K | -33.48K | 4.58K |
| Net Income | -3.12M | -2.61M | -2.05M | -3.38M | -3.84M | -3.84M | -2.90M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | -1.91M | -2.08M | -398.09K | -617.13K | -581.86K | -1.75M | -130.06K | -762.98K | -3.18M |
| Net Income Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,175.93% | -1,175.93% | -179.63% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | -533.64% | -110.28% | -21.37% | -79.56% | -82.05% | -1,562.55% | -33.54% | -593.21% | -45,465.96% |
| EPS | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| Weighted Avg Shares Out | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
| Weighted Avg Shares Out (Dil) | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Oct. 25, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing, today,...
DIAGNOS Announces the Engagement of Market Maker Consultant
BROSSARD, Quebec, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
DIAGNOS Announces Grant of Stock Options
BROSSARD, Quebec, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces a grant of...
DIAGNOS Announces Voting Results of Meeting of Shareholders
BROSSARD, Quebec, Sept. 26, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the voting results...
DIAGNOS Announces Variation in One Insider Ownership
BROSSARD, Quebec, Sept. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that as a result of the issuance of 8,333,333 common shares (each, a “Share”) as...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Sept. 20, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing, today,...
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
BROSSARD, Quebec, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
BROSSARD, Quebec, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
BROSSARD, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of...
DIAGNOS celebrates the launch of Labtician's new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
BROSSARD, Quebec, May 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is thrilled to...
Source: https://incomestatements.info
Category: Stock Reports